GHRS — GH Research PLC stock price, charts and financials

QT78GH Research PLC

GH Research PLC (NASDAQ: GHRS) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
29.69
-0.58-1.92%
OverviewShort InterestFilings
GHRSQT78GH Research PLC·NASDAQ
29.69-1.92%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
TSHA-0.84%$6.50ZBIO-1.59%$31.91MESO+5.02%$16.74STOK-1.64%$32.17AUPH-2.37%$15.47ABCL+32.14%$9.16VRDN-2.54%$22.99OCUL+0.38%$9.22
Snapshot
Index-P/E-EPS (ttm)-Insider Own-Shs Outstand68.56MPerf Week7.84%
Market Cap2.08BForward P/E-EPS next Y-1.86Insider Trans-Shs Float50.88MPerf Month11.29%
Enterprise Value1.83BPEG1.94EPS next Q-Inst Own-Short Float3.82%Perf Quarter44.07%
Income-62.26MP/S0.00EPS this Y-Inst Trans-Short Ratio7.45Perf Half Y121.60%
Sales0.00P/B7.13EPS next Y-41.67%ROA-20.49%Short Interest1.95MPerf YTD138.35%
Book/sh-P/C-EPS next 5Y-ROE-19.83%52W High30.84 -3.72%Perf Year149.14%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-25.28%52W Low11.10 167.40%Perf 3Y126.57%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility5.31% 5.53%Perf 5Y53.65%
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-22.67%Oper. Margin0.00%ATR (14)1.56Perf 10Y-
Dividend Ex-Date-Quick Ratio23.04Sales Y/Y TTM-Profit Margin0.00%RSI (14)66.06Recom2.00
Dividend Gr. 3/5Y-Current Ratio23.04EPS Q/Q-63.16%SMA207.39%Beta1.31Target Price45.60
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA5018.05%Rel Volume1.23Prev Close30.27
Employees73LT Debt/Eq0.00EarningsNov 05SMA20065.14%Avg Volume275.19KPrice29.69
IPO DateJun 25, 2021Option/ShortYes / YesEPS/Sales Surpr.-5.68% -Net Debt/EBITDA4.34Volume337,152Change-1.92%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-07-26ReiteratedCantor FitzgeraldOverweight$35 → $40
Aug-07-26ReiteratedGuggenheimBuy$34 → $40
Aug-06-26ReiteratedNeedhamBuy$32 → $39
Jul-27-26InitiatedWells FargoOverweight$44
May-19-26ReiteratedHC Wainwright & Co.Buy$35 → $65
May-15-26ReiteratedCantor FitzgeraldOverweight$35
Mar-10-26ReiteratedGuggenheimBuy$29 → $34
Mar-06-26ReiteratedNeedhamBuy$29 → $32
Jan-23-26ReiteratedRBC CapitalOutperform$40
Jan-06-26ReiteratedWolfe Research$39
Latest News
Aug-06-26
Aug-06-2602:19PM
Needham Maintains Buy on GH Research, Raises Price Target to $39Benzinga
07:00AM
GH Research Reports Second Quarter 2026 Financial Results and Provides Business Updateglobenewswire.com
Jul-27-26
Jul-27-2608:49AM
Wells Fargo Initiates Coverage On GH Research with Overweight Rating, Announces Price Target of $44Benzinga
Jul-16-26
Jul-16-2612:36PM
Why Is GH Research Stock Trading Higher on Thursday?Benzinga
Jul-14-26
Jul-14-2607:53AM
CleanSpark shares surge after company secures $6.6B data center lease agreementproactiveinvestors.com
07:20AM
Tower Semiconductor shares jump as company announces Japan expansion to boost silicon photonics capacityproactiveinvestors.com
Jul-13-26
Jul-13-2603:18PM
Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies saysproactiveinvestors.com
Company

GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue
000————
Cost of Goods Sold Incl. D&A
000————
Gross Profit
000————
Selling, General and Administrative Excl. Other221511————
Research and Development393530————
Other Operating Expense-100————
Operating Income-61-50-41————
Interest Expense011————
Unusual Expense
———————
Non-Operating Income (Expense)13126————
Net Income Before Taxes-48-39-36————
Income Taxes
000————
Consolidated Net Income-48-39-36————
Net Income From Continuing Operations-48-39-36————
Net Income-48-39-36————
EPS (Recurring)-0.79-0.75-0.68————
EPS (Basic, Before Extraordinaries)-0.79-0.75-0.68————
EPS (Diluted)-0.79-0.75-0.68————
EBITDA-47-39-35————
Other After Tax Adjustments
———————
Stock Option Compensation Expense
———————
Price To Earnings Ratio
———————
Price To Sales Ratio
———————
Gross Margin
———————
Operating Margin
———————
Net Margin
———————
Shares Outstanding615252————
Market Capitalization775364302————
Operating Lease Expense
———————
Unlock full historical data
See years of past statements with Premium.
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.